A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)

Inclusion Criteria:

Cisplatin Combination Expansion:

Arm 1:Patients with TNBC with no prior cytotoxic chemotherapy therapy in the metastatic setting; Arm 2: Patients with TNBC and one or two prior cytotoxic therapies in the metastatic setting.

Arm A: castrate resistant prostate cancer, advanced breast cancer, or non-small cell lunch cancer that are candidates for treatment with a docetaxel-based combination.
Arm B: Urothelial transitional cell cancer, triple negative breast cancer, ovarian cancer or non small cell lunch cancer that are candidates for a cisplatin-based combination.
Arm C: Her2+ breast cancer refractory to prior herceptin or lapatinib, her2+ esophagal-gastric cancer, head and neck squamous cell cancer, or non small cell lunch cancer that are candidates for treatment with a dacomitinib-based combination.
Availability of archival tumor biopsy sample or willing to provide fresh biopsy if not available.
Eastern Cooperative Oncology Group [ECOG] performance must be 0 or 1.
Adequate bone marrow, renal and liver function.

Exclusion Criteria:

Prior therapy for Cisplatin Combination Expansion:

Prior platinum (carboplatin or cisplatin) in either the adjuvant or metastatic setting;
Prior radiation to >25% bone marrow as estimated by the Investigator.
Patients with known symptomatic brain metastases.
Chemotherapy, radiotherapy, biologics or investigational agent within 4 weeks of the lead-in dose.
Major surgery within 4 weeks of the baseline disease assessments.
>2 prior regimens containing cytotoxic chemotherapy in the metastatic setting.
Active bacterial, fungal or viral infection.
Uncontrolled or significant cardiovascular disease.